Ask about this productRelated genes to: CD44 antibody
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: CD44 antibody
Related articles to: CD44 antibody
- Despite advances in oncology, the dual challenge of achieving precise tumor-targeted therapy while simultaneously activating antitumor immunity remains a major clinical barrier. In this study, we engineered a biocompatible copper-based platform, hyaluronic acid (HA) modified Cu ions based therapeutic (B-Cu/HA), that integrates selective tumor targeting, intrinsic cytotoxicity, and immune activation within a single therapeutic system. Leveraging the HA-CD44 interaction, B-Cu/HA exhibited preferential accumulation and prolonged retention in CD44-overexpressing tumors, while maintaining an excellent biosafety profile. Across multiple cancer models, B-Cu/HA robustly inhibited tumor progression. Mechanistically, it induced cuproptosis through upregulation of FDX1 and aggregation of lipoylated DLAT, and triggered ROS-mediated activation of the cGAS-STING pathway, promoting immunogenic cell death. Transcriptomic analysis revealed activation of hypoxia and cytokine signaling pathways, aligning with enhanced CD8 T-cell cytotoxicity and remodeling of the tumor immune microenvironment. The animal models studies demonstrated that B-Cu/HA significantly suppressed tumor growth without systemic toxicity, and synergistically enhanced the efficacy of the immune checkpoint inhibitors anti-TIGIT. Together, these findings establish B-Cu/HA as a multifunctional, immunomodulatory formulation that offers a clinically translatable strategy to enhance tumor immunotherapy and overcome resistance in CD44-overexpressing tumors. - Source: PubMed
Publication date: 2026/06/13
Fang YifengTu MengyanTu XinruZhang HongboLi YangyangXu Junfen - Chronic inflammation of the airways plays a crucial role in disease progression and symptom exacerbation in patients with chronic obstructive pulmonary disease (COPD). Nitric oxide (NO) relaxes airway smooth muscle and regulates the inflammatory response. The multifunctional therapeutic effects of NO are highly attractive for COPD treatment. However, the practical difficulties in long-term and targeted administration remain a limitation. This work presents an inhaled nanotherapeutic, termed AIR (Anti-Inflammatory Relaxer), engineered for targeted NO delivery to proinflammatory M1 macrophages. AIR is constructed from dendritic mesoporous silica nanoparticles (DMSNs) functionalized with hyaluronic acid (HA) and diazeniumdiolates (NONOates). HA enables selective targeting of CD44-overexpressing M1 macrophages, thereby leading to their polarization into anti-inflammatory phenotypes. Moreover, disulfide bonds in AIR are cleaved by intracellular glutathione, which is present at millimolar concentrations, ensuring excellent biocompatibility. Overall, these inhaled nanotherapeutics have great potential in relieving chronic inflammation in COPD while reducing bioaccumulation in the lungs. - Source: PubMed
Publication date: 2026/06/18
Oh YoogyeongKim TaihyunPark KyungtaeMoon Chae-WonJeong YunseoLee YoojinHa Sang-JunJung Se YongHong Jinkee - Retinoblastoma (RB), a malignant intraocular tumor, represents a critical public health challenge, particularly for pediatric populations, underscoring the urgent need for innovative therapeutic approaches and novel drug development. In this study, amentoflavone (AMF) was identified as a potential agent against RB cancer stem cells (RBCSCs). While CCK8 assays revealed moderate anti-proliferative effects of AMF on RB cell lines, migration and invasion assays demonstrated its potent ability to suppress cancer cell motility. Tumorsphere formation assays further indicated that AMF significantly reduces RB cell stemness. qRT-PCR analysis showed that AMF downregulates expression of stem cell markers (CD44, CD133, Oct4, and Nanog) in a dose-dependent manner. In vivo studies confirmed that AMF inhibits tumor metastasis and prolongs survival in RB mouse models. To elucidate its mechanism of action, RNA sequencing, molecular docking, and surface plasmon resonance (SPR) were employed. These analyses revealed that AMF directly targets smoothened (SMO) to disrupt the SHh signaling pathway, thereby suppressing RB stem cell (RBSC) self-renewal and tumor progression. This work uncovers a previously unreported mechanism by which AMF hinders RB development and highlights its potential as a promising therapeutic candidate for this aggressive pediatric cancer. - Source: PubMed
Publication date: 2026/06/14
Li CuipingYu XinKong XiangfenZheng QianPan YuQi Dengmei - Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin malignancies with limited reliable biomarkers for early detection and prognosis. This study integrated bulk and single‑cell transcriptomic data to identify post‑translational modification-related key genes and to characterise cellular and immune alterations in cSCC. - Source: PubMed
Publication date: 2026/05/27
Li WentingXu TaoDing YuChen JianghanYao GuotaiWu SiyuWu Jianhua - Heat stress (HS) impairs cattle reproductive functions decreasing livestock production. However, HS response in cattle reproductive cumulus cells is still understudied due to limited cell line and comprehensive omics data. This study aims to establish immortalized cumulus cells from Hanwoo cattle as HS model and to explore its HS-response through molecular markers including transcriptomics and proteomics approaches. - Source: PubMed
Publication date: 2026/06/15
Shaleh IsmailKim Sung WooPark Tae SubPark Joonghoon